Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Avis between February 16, 2024 and February 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Insights - Broad Arrow Auctions, a subsidiary of Hagerty, is launching a new auction event called the Zoute Concours Auction in collaboration with Zoute Grand Prix Car Week, scheduled for October 10, 2025, in Belgium [1][2][3] - The auction will feature approximately 70 exceptional collector cars, showcasing a variety of categories and price points, enhancing Broad Arrow's presence in the European market [1][2][3] Company Overview - Broad Arrow Auctions was founded in 2021 and has quickly become a leading global collector car auction house, known for its high-quality offerings and rapid growth in the auction segment [5] - The company recently debuted in Europe as the official auction partner for BMW AG at the Concorso d'Eleganza Villa d'Este, achieving €31.2 million in sales with 78% of lots sold [3][5] Event Details - The Zoute Grand Prix Car Week is a prestigious five-day festival that combines exceptional automobiles, art, and luxury lifestyle, attracting collectors and enthusiasts from around the world [2][7] - The Zoute Concours Auction will coincide with the Zoute Concours d'Élégance, further elevating the event's profile and providing a platform for showcasing automotive elegance [2][3][7] Strategic Partnerships - The partnership between Broad Arrow and Zoute Grand Prix aims to enhance the international character of the event and expand both companies' global reach [3][7] - This collaboration is seen as a natural fit, driven by a shared vision of excellence and ambition [3]

Core Insights - CARsgen Therapeutics has announced positive results from the pivotal Phase II clinical trial of satricabtagene autoleucel ("satri-cel") for treating Claudin18.2-positive advanced gastric/gastroesophageal junction cancer, which were published in The Lancet and presented at the 2025 ASCO Annual Meeting [1][2][3] Company Overview - CARsgen Therapeutics is focused on developing innovative CAR T-cell therapies to address unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases [7] - The company has established comprehensive capabilities for CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production [7] Clinical Trial Details - The CT041-ST-01 trial is the first randomized controlled clinical study of CAR-T cell therapy for solid tumors, demonstrating significant clinical benefits such as improved progression-free survival (PFS), overall survival (OS), and tumor response rates in heavily pretreated patients [4] - The trial results indicate that satri-cel offers breakthrough efficacy for patients with limited treatment options and poor prognosis [4] Regulatory Designations - Satri-cel has received Breakthrough Therapy Designation and Priority Review from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for treating Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma [6] - The company plans to submit a New Drug Application (NDA) for satri-cel to the NMPA, anticipating it to be the first commercially available CAR-T product for solid tumors [4][6] Future Development Plans - CARsgen is exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies to intervene earlier in the disease course and extend patient survival [4] - Ongoing trials include various phases for treating advanced gastric/gastroesophageal junction adenocarcinoma and pancreatic cancer [5]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avis To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Avis between February 16, 2024 and February 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, May 31, 2025 /PRNewswire/ -- Faruqi & Faruqi, L ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR). Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=150515&from=3 CLASS PERIOD: February 16, ...

NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR).Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=150498&from=4CLASS PERIOD: February 16, 2024 to ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Avis Budget securities between February 16, 2024, and February 10, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 24, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which significantly accelerated in Q4 2024 [5]. - This acceleration reportedly shortened the useful life of Avis Budget's vehicles in the Americas segment, leading to billions of dollars in impairment charges and substantial losses [5]. - The lawsuit claims that these actions had a significant negative impact on Avis Budget's financial results, overstating the company's financial and business prospects [5].

Group 1 - Avis Budget Group (NASDAQ: CAR) has experienced a significant rally, with shares increasing by 9% from the previous year, following lows in March [1] - The company's business model is highly leveraged to the residual value of used cars, positioning it as a potential beneficiary in the current market environment [1] - The analyst emphasizes a contrarian investment strategy based on macroeconomic views and turnaround stories to achieve favorable risk/reward profiles [1]

Company Overview - CARsgen Therapeutics Holdings Limited is focused on developing innovative CAR T-cell therapies to address unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases [3] - The company has established end-to-end capabilities for CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production [3] - CARsgen aims to improve the safety profile, enhance efficacy in treating solid tumors, and reduce treatment costs of CAR T-cell therapies [3] Product Development - Satri-cel is an autologous CAR T-cell product candidate targeting Claudin18.2, with a primary focus on treating Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) and pancreatic cancer [2] - The product has received Priority Review from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for patients who have failed at least two prior lines of therapy [1] - Satri-cel has been granted Breakthrough Therapy Designation by the CDE in March 2025 and has received Orphan Drug designation from the U.S. FDA in September 2020 [2] Clinical Trials - Ongoing clinical trials for Satri-cel include a confirmatory Phase II trial for advanced G/GEJA in China, a Phase Ib trial for pancreatic cancer adjuvant therapy, and a Phase 1b/2 trial for advanced gastric or pancreatic adenocarcinoma in North America [2] - The company is also conducting investigator-initiated trials to explore the use of Satri-cel as a consolidation treatment following adjuvant therapy in patients with resected G/GEJA [2]

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...